Peripheral T‐cell lymphoma immunophenotype in a patient with a history of <scp>Muromonab‐CD3</scp> therapy: A case report and a diagnostic dilemma
Joerg Hoffmann(Philipps University of Marburg), Cornelia Brendel(Philipps University of Marburg), Andreas Klameth(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Martin Rußwurm(Universitätsklinikum Gießen und Marburg)
Cited by 0
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573